ஐ.எஸ்.எஸ்.என்: 2155-9880
Anil Potdar1, Chetan Gharat1,2*, Kamlesh Patel2
Background: Coronary Artery Disease (CAD) remains a leading cause of mortality, with Indians exhibiting a notably elevated risk compared to other populations. Digital Therapeutics (DTx), such as smartphone applications, offer a promising solution by providing personalized, technology-driven interventions to improve healthcare outcomes. Methods: This interim, prospective, single-centre cohort study aimed to evaluate the effectiveness of a clinical evidence-based software-driven therapeutic LYFE app intervention in combination with Standard of Care (SOC) compared to SOC alone among post-Percutaneous Coronary Intervention (PCI) patients with CAD and/or ACS. Results: A total of 86 patients were enrolled, with 42 receiving the LYFE app intervention alongside SOC and 44 receiving SOC alone. At 3 months, the LYFE group experienced significantly greater improvements in mean Dartmouth COOP Scales compared to the SOC group (p<0.001). The mean change from baseline to 3 months in SBP was higher in the LYFE group compared to the SOC group (6.1 vs. 1.9). LYFE showed favourable trends in Low Density Lipoprotein (LDL) (66.5 mg/dL vs. 61.3 mg/dL) and glycated Haemoglobin (HbA1c) (7.6% vs. 6.9%) from baseline to 3 months; which attributed to improved adherence to medications and app assistance. At 3 months, participants in the LYFE group showed higher medication adherence, with 85.4% reporting 'hardly or no difficulty’ in remembering their medication compared to the SOC group (42.1%). Compared to the SOC group, the LYFE group showed superior adherence in terms of physical exercise (92.7% vs. 28.9%) and diet (95.1% vs. 50.0%) at 3-months. Conclusion: The combination of LYFE app with SOC, significantly improved medication adherence, physical exercise adherence, and diet habits compared to SOC alone. It also led to notable enhancements in Quality of Life (QoL), reductions in SBP and PR, improved blood pressure control, and positive changes in biochemical parameters such as LDL cholesterol and HbA1c levels.